How Muse Cells Work: S1P Homing, Stress Tolerance and What the Evidence Shows

Regenerative medicine has introduced a range of cell-based therapies over the past two decades, and among the most recent additions are multi-lineage differentiating stress-enduring (Muse) cells. First characterized by Kuroda, Dezawa and colleagues in 2010, Muse cells are a small population of cells found in adult tissues—principally bone marrow and adipose tissue—that carry a surface marker called SSEA-3 and display an unusual tolerance to environmental stress. Unlike embryonic stem cells or induced pluripotent stem cells, Muse cells exist naturally in the body, and their discovery opened questions about whether these cells could be expanded, delivered intravenously, and guided to sites of injury. Understanding how do Muse cells work requires examining the biology behind their stress resilience, the molecular signals that direct them to damaged tissue, and the early-stage clinical evidence that has emerged from controlled trials in Japan and elsewhere. This article reviews the published mechanisms, the key peer-reviewed studies that define the field, and the important unknowns that remain.

Discovery and Defining Characteristics

Muse cells were identified by Kuroda, Dezawa and colleagues in a 2010 study published in the Proceedings of the National Academy of Sciences. The research team isolated cells from human bone marrow and subjected them to extended culture under low-serum, stress-inducing conditions. A small subset of cells—comprising roughly one to three percent of the starting population—survived and continued to proliferate. These surviving cells were uniformly positive for the embryonic stem cell marker SSEA-3, a glycolipid antigen not typically expressed on most adult cells. When the SSEA-3-positive cells were subjected to differentiation protocols in vitro, they gave rise to cells representing all three germ layers: endoderm, mesoderm, and ectoderm. This trilineage capacity, combined with stress tolerance, distinguished Muse cells from conventional mesenchymal stem cells and led to the hypothesis that they might function as an endogenous repair system in adult tissues.

Wakao, Dezawa and colleagues extended this work in a 2011 PNAS paper, demonstrating that Muse cells isolated from bone marrow, adipose tissue, and dermal fibroblasts could differentiate spontaneously when placed in environments that mimic injury. The cells did not require genetic reprogramming or forced differentiation protocols. Instead, they appeared to sense cues from damaged tissue and adopt phenotypes consistent with local cell types. The authors proposed that Muse cells represent a pluripotent-like reserve in adult tissues, maintained at low frequency and mobilized in response to severe stress or injury. These foundational studies established the defining properties—SSEA-3 expression, stress endurance, trilineage differentiation capacity, and spontaneous differentiation—but they did not yet address how the cells might reach distant sites of injury after intravenous delivery.

The S1P–S1PR2 Homing Mechanism

A central question in Muse cell biology is how these cells, when delivered into the bloodstream, locate and accumulate at sites of tissue damage. Yamada and colleagues addressed this question in a 2018 study published in Circulation Research. The research team focused on sphingosine-1-phosphate (S1P), a lipid signaling molecule that is released by damaged and dying cells. Using an animal model, the investigators showed that Muse cells express a receptor called S1P receptor 2 (S1PR2) on their surface and that cells lacking this receptor failed to migrate toward areas of injury. When Muse cells were administered intravenously, cells expressing functional S1PR2 accumulated preferentially in damaged tissue, whereas cells with S1PR2 blocked by pharmacologic inhibitors or genetic knockout remained in circulation or were cleared by the liver and spleen.

The Yamada 2018 study demonstrated that the S1P–S1PR2 axis functions as a homing mechanism. Injured tissue releases S1P into the local microenvironment and the bloodstream. Circulating Muse cells detect the S1P gradient through S1PR2, triggering intracellular signaling cascades that promote migration, adhesion, and extravasation into the damaged area. Once inside the tissue, Muse cells encounter additional cues—inflammatory cytokines, extracellular matrix fragments, hypoxia—that are thought to guide their differentiation into cell types appropriate to the local environment. This homing mechanism is foundational to understanding how do Muse cells work after intravenous administration, because it explains how a small number of cells delivered systemically can reach a focal site of injury without requiring direct injection into the affected organ.

The S1P–S1PR2 pathway is not unique to Muse cells; other cell types, including certain immune cells and endothelial progenitors, also respond to S1P gradients. What appears distinctive about Muse cells is the combination of homing capacity, stress tolerance, and pluripotent-like differentiation potential. However, the Yamada study was conducted in an animal model, and translating the homing mechanism to human patients involves several uncertainties. Human blood flow dynamics, immune responses, and the magnitude of S1P release in various injury contexts may differ significantly from experimental conditions. The extent to which S1P–S1PR2 homing operates in living patients remains an area of active investigation.

Stress Tolerance and Survival in Hostile Environments

One of the hallmarks of Muse cells is their ability to survive conditions that kill most other cell types. Standard mesenchymal stem cells, for example, undergo apoptosis when exposed to prolonged serum deprivation, oxidative stress, or inflammatory mediators. Muse cells, by contrast, continue to proliferate under these conditions. This stress tolerance is thought to be mediated by intrinsic cellular machinery, including enhanced expression of anti-apoptotic proteins, efficient DNA repair pathways, and robust antioxidant systems. The mechanistic details are still being worked out, but the practical implication is that Muse cells may retain viability after intravenous infusion, passage through the pulmonary circulation, and entry into inflamed or ischemic tissue.

Stress endurance also influences how Muse cells behave once they reach an injury site. Damaged tissue is typically characterized by low oxygen tension, acidic pH, high levels of reactive oxygen species, and a dense infiltrate of immune cells. These conditions would be expected to impair or kill most transplanted cells within hours. Muse cells, however, appear to persist and even proliferate in these environments. Laboratory studies have shown that Muse cells upregulate genes associated with hypoxia adaptation and cellular stress response when cultured under low-oxygen conditions. Whether this translates into prolonged engraftment and functional integration in human tissues is not yet established, but the in vitro data suggest that stress tolerance is a core feature of how do Muse cells work in regenerative applications.

It is important to recognize that stress tolerance does not ensure indefinite survival or engraftment. Even Muse cells have limits. Very few transplanted cells of any kind persist beyond a few weeks in most preclinical models, and the same is likely true in patients. The working hypothesis is that Muse cells exert their effects during a transient window—secreting growth factors, modulating inflammation, differentiating into a small number of replacement cells—and then either die, become quiescent, or are cleared by the immune system. This transient activity model contrasts with the idea of permanent tissue replacement and reflects a more realistic understanding of cell therapy dynamics.

Immune Privileged Properties and Allogeneic Use

A significant practical advantage of Muse cells is that they appear to evade immune recognition more effectively than many other cell types. This property is often described as immune privilege, though the term is somewhat imprecise. Muse cells express low levels of major histocompatibility complex (MHC) class I molecules and lack MHC class II expression. They also secrete factors such as transforming growth factor beta and prostaglandin E2 that dampen local immune responses. In animal studies, allogeneic Muse cells—cells from a donor of the same species but a different individual—have been infused without inducing acute rejection, even in the absence of immunosuppressive drugs.

Human trials of Muse cell therapy have use this immune-privileged behavior by using allogeneic, off-the-shelf cell products derived from healthy adult donors. Cells are expanded in culture, cryopreserved, and thawed for infusion without patient-specific customization. This contrasts with autologous therapies, which require harvesting cells from the patient, expanding them in the laboratory, and reinfusing them weeks later. The allogeneic approach is logistically simpler and potentially more scalable, but it introduces questions about batch-to-batch variability, donor-to-donor differences in cell potency, and the long-term immunologic consequences of repeated infusions. The published studies to date have not reported serious immune-related adverse events, but follow-up periods remain relatively short.

Understanding how do Muse cells work in the context of allogeneic transplantation also requires considering the role of the recipient's immune system. Even if Muse cells are not immediately rejected, they may be subject to chronic immune surveillance that limits their persistence or function. The absence of acute rejection does not necessarily mean the cells are invisible to the immune system; it may simply mean that immune clearance occurs slowly or that the cells exert their effects before being cleared. These nuances underscore the difference between laboratory observations and real-world clinical outcomes.

Published Human Evidence: What the Trials Show

The first controlled human study of Muse cell therapy was conducted by Noda and colleagues and published in 2020 in Circulation Journal. This first-in-human Japanese safety study enrolled a small cohort of patients and evaluated the safety and preliminary efficacy of intravenously delivered allogeneic Muse cells. The trial reported no serious adverse events directly attributable to the cell infusion, and the investigators observed modest improvements in functional measures in some participants. However, the study was not powered to detect statistically significant efficacy, and the authors emphasized that larger, randomized trials would be necessary to confirm any clinical benefit.

A subsequent randomized, double-blind Japanese trial was published by Niizuma and colleagues in 2023 in Neurology. This study used a placebo-controlled design and enrolled a larger patient cohort. Participants received either Muse cells or a placebo infusion, and the primary endpoint was a functional improvement scale. The results showed a statistically significant difference favoring the Muse cell group, but the magnitude of the effect was modest and not observed uniformly across all participants. Approximately one-third of supported patients showed meaningful improvement, while the remainder showed little or no change. The authors noted that individual responses varied widely and that additional research would be needed to identify which patients are most likely to benefit.

These trials provide the strongest published evidence for Muse cell therapy in humans, but they also illustrate the uncertainties that persist. Both studies were conducted in Japan using a specific cell product (CL2020), and the extent to which the findings generalize to other patient populations, injury contexts, or cell preparations is unknown. The trials were relatively small, with follow-up periods of several months to one year, and they did not address long-term outcomes or the durability of any observed effects. The literature is not uniformly positive; the Niizuma 2023 trial's primary endpoint was modest, and the variation in individual responses suggests that Muse cell therapy is not a one-size-fits-all solution.

Additional safety data come from earlier trials involving other types of mesenchymal stem cells. Hare and colleagues published a 2009 safety trial in the Journal of the American College of Cardiology, evaluating intravenous allogeneic MSCs in a randomized, controlled design. The study found no serious safety signals and provided a foundation for subsequent investigations into various cell types. Bartolucci and colleagues reported a 2017 trial in Circulation Research (the RIMECARD study) using umbilical-cord-derived MSCs, which showed functional improvements averaging several points on clinical scales. These studies are not Muse cell trials per se, but they inform the safety and plausibility of intravenous cell delivery in general, and they highlight the importance of controlled trial design in evaluating regenerative therapies.

What Remains Unknown

Despite the mechanistic insights and early-stage clinical data, many fundamental questions about how do Muse cells work remain unanswered. The precise fate of infused cells in human tissues is not well characterized. Do the cells engraft and persist, or do they exert their effects transiently and then disappear? If differentiation occurs in vivo, what signals control the lineage choices, and how often does functional integration into host tissue actually happen? The published trials have not included detailed imaging or biopsy studies to track cell fate, so these questions remain largely speculative.

Another open question concerns the dose-response relationship. The trials to date have used fixed cell doses based on preclinical data, but it is not clear whether higher doses would produce better outcomes, reach a plateau, or even cause harm through immune activation or microvascular occlusion. Similarly, the optimal timing of infusion relative to the onset of injury is unknown. Animal studies suggest that early intervention is more effective than delayed therapy, but translating this to clinical practice is complicated by the realities of patient access, diagnosis, and logistical constraints.

The mechanisms underlying individual variability in response are also poorly understood. Why do some patients improve while others do not? Potential explanations include differences in baseline immune status, the severity and chronicity of tissue damage, genetic factors influencing S1P signaling or cell homing, and variations in the cell product itself. Identifying biomarkers that predict response would be a major advance, but no such markers have been validated. Until these questions are addressed through larger, well-controlled studies, the clinical application of Muse cell therapy will remain investigational.

The Role of Physician Evaluation

Patients considering investigational cell therapies should understand that mechanism of action is not the same as proof of clinical benefit. Dr. Charles Pereyra, MD, emphasizes that while the published science on Muse cells is intriguing, the human data remain early-stage and limited to a small number of controlled trials. A thorough medical evaluation is essential to determine whether an individual is a plausible candidate for any investigational therapy. This evaluation should include a review of the patient's medical history, current medications, underlying conditions, and prior responses to conventional therapies. Not every patient with tissue damage or functional impairment is an appropriate candidate, and candidacy cannot be determined from a brief questionnaire or phone call.

Dr. Charles Pereyra also stresses the importance of realistic expectations. The published trials show modest effects, wide individual variability, and outcomes that cannot be predicted with certainty. Regenerative therapies are not a substitute for evidence-based medical care, and patients should continue to follow the guidance of their primary physicians and specialists. Investigational therapies should be considered as part of a comprehensive care plan, not as a last-ditch alternative when conventional options have been exhausted. Physician-supervised Muse cell therapy is now available at centers in the United States, which means patients no longer need to travel overseas to access these investigational options. However, availability does not imply that the therapy is proven, FDA-approved, or appropriate for every individual.

Broader Context: Comparing Muse Cells to Other Regenerative Approaches

Muse cells are one of several cell-based approaches under investigation for tissue repair. Mesenchymal stem cells from bone marrow or adipose tissue have been studied for decades and share some properties with Muse cells, including trophic factor secretion and immunomodulatory effects. Platelet-rich plasma (PRP) is another widely used regenerative intervention, particularly for musculoskeletal and dermatologic applications. Gentile and Garcovich reviewed PRP for androgenetic alopecia in a 2019 systematic review in Cells, finding that while some studies reported improvements in hair density, the quality of evidence was variable and the mechanisms remained incompletely understood. Shin and colleagues reported a small 2015 study in the International Journal of Dermatology using adipose-derived stem cell conditioned media for alopecia, with modest results that did not reach statistical significance in all measures.

What distinguishes Muse cells from these other approaches is the combination of stress tolerance, SSEA-3 expression, trilineage differentiation capacity, and S1P-mediated homing. Whether these features translate into superior clinical outcomes is an empirical question that can only be answered through head-to-head comparative trials. No such trials have been published, and it is possible that different regenerative modalities work best in different clinical contexts. The field is still in its early stages, and the evidence base for all of these approaches remains investigational.

Regulatory Status and Patient Awareness

It is critical for patients to understand that Muse cell therapy is not FDA-approved. The trials published by Noda and colleagues, Niizuma and colleagues, and others were conducted under investigational protocols with regulatory oversight in their respective countries. In the United States, cell therapies that involve more than minimal manipulation or are used for non-homologous purposes generally require an investigational new drug (IND) application and approval from the Food and Drug Administration before they can be studied in clinical trials. Clinics offering cell-based therapies should be transparent about their regulatory status, the evidence supporting the intervention, and the risks and limitations.

Patients should be wary of providers who make sweeping claims about efficacy, certain outcomes, or the ability to address a wide range of unrelated conditions. The published evidence on Muse cells is specific to certain injury models and clinical contexts, and extrapolating those findings to other diseases or conditions is not scientifically justified. A reputable provider will present the evidence honestly, acknowledge the gaps in knowledge, and involve patients in shared decision-making rather than overpromising results.

Future Directions in Muse Cell Research

The next generation of Muse cell research will likely focus on several key areas. First, larger randomized controlled trials are needed to confirm the preliminary findings and establish the conditions under which the therapy is most effective. Second, mechanistic studies using advanced imaging and molecular profiling can help clarify cell fate, differentiation pathways, and the duration of engraftment in human tissues. Third, biomarker discovery efforts may identify subgroups of patients who are most likely to respond, enabling more personalized and efficient use of the therapy. Fourth, combination approaches—pairing Muse cells with targeted drug therapies, biomaterial scaffolds, or rehabilitation protocols—may enhance outcomes beyond what cells alone can achieve.

Understanding how do Muse cells work will also require better preclinical models that more accurately recapitulate human physiology. Many of the foundational studies were conducted in rodents, which differ from humans in immune system function, tissue architecture, and injury response kinetics. Developing large-animal models or using human tissue organoids may provide more reliable predictions of clinical performance. Advances in cell manufacturing, such as optimized culture conditions, quality-control assays, and cryopreservation protocols, will be essential for producing consistent, potent cell products at scale.

Finally, regulatory pathways for cell therapies are evolving, and greater clarity on approval standards, post-market surveillance, and long-term safety monitoring will be critical for bringing investigational therapies from the laboratory into routine clinical practice. Patients, clinicians, and researchers all have a stake in ensuring that the development of Muse cell therapy is guided by rigorous science, ethical transparency, and a commitment to patient welfare.

Frequently Asked Questions

How do Muse cells differ from standard mesenchymal stem cells?

Muse cells are a subset of cells identified by SSEA-3 expression and exceptional stress tolerance, as first characterized by Kuroda, Dezawa and colleagues in 2010. Unlike conventional mesenchymal stem cells, Muse cells survive prolonged culture under low-serum, stress-inducing conditions and demonstrate trilineage differentiation capacity without requiring genetic reprogramming. They also express the S1P receptor 2, which enables them to home to damaged tissue after intravenous delivery, as shown by Yamada and colleagues in 2018. Standard mesenchymal stem cells may lack these properties and do not reliably home to injury sites when delivered systemically.

What does the clinical evidence show about Muse cell therapy?

The strongest published evidence comes from two Japanese trials. Noda and colleagues reported a first-in-human safety study in 2020, finding no serious adverse events and modest functional improvements in some participants. Niizuma and colleagues published a randomized, double-blind trial in 2023 showing statistically significant but modest improvements on the primary endpoint, with wide individual variability. Approximately one-third of participants showed meaningful benefit, while others showed little change. The therapy remains investigational, and larger studies are needed to confirm efficacy and identify which patients are most likely to respond.

Are Muse cells FDA-approved for any medical condition?

No. Muse cell therapy is not FDA-approved. The trials conducted by Noda, Niizuma, and other investigators were performed under investigational protocols with regulatory oversight in Japan. In the United States, cell therapies that involve more than minimal manipulation or non-homologous use require an investigational new drug application and FDA approval before clinical use. Patients considering Muse cell therapy should verify that the provider operates under appropriate regulatory oversight and presents the investigational status honestly.

What are the main unknowns about how Muse cells function in the body?

Many fundamental questions remain unanswered. The precise fate of infused cells—whether they engraft permanently, differentiate into functional tissue, or exert transient effects before disappearing—is not well characterized in humans. The optimal cell dose, timing of infusion, and patient selection criteria have not been established. The mechanisms underlying individual variability in response are poorly understood, and no validated biomarkers exist to predict which patients will benefit. Long-term safety and durability of any observed effects are also unknown, as published follow-up periods remain relatively short.

At Springs Rejuvenation, stem cell and exosome therapies are used together as part of a personalized regenerative protocol.